

Financial Tear Sheet

Corporate Profile

Perseon is dedicated to developing innovative technologies to fight cancer. Our products treat soft tissue tumors with precision-focused microwave energy, expanding treatment options for patients and healthcare providers everywhere. Backed by a seasoned executive team, we are a market leader in energy ablation, generating growing revenue from our proprietary MicroThermX® line of products.

Primary IR Contact

Tricia Ross


Phone: 310-622-8226

E-mail:

TRoss@finprofiles.com

Stock Performance

| PRSN (Common Stock) | |
|----------------------------|--------------------|
| Exchange | NASDAQ (US Dollar) |
| Financial Status Indicator | C |
| Price | \$0.07 |
| Change (%) | ▼ 0.02 (22.22%) |
| Volume | 148,680 |
| 52 Week High | \$7.50 |
| 52 Week Low | \$0.07 |
| Market Cap | \$644,577 |
| Rolling EPS | -2.53 |
| PE Ratio | 0 |
| Shares Outstanding | 9,766,323 |



Data as of 01/15/16 4:00 p.m. ET

Recent Headlines

12/22/15

[Galil Medical Tender Offer to Acquire Perseon Corporation Expires](#)

11/30/15

[Galil Medical and Perseon Corporation Announce Tender Offer/Merger Information Call](#)

10/27/15

[Galil Medical Enters Into Agreement to Acquire Perseon Corporation to Create Leader in Ablation Treatment for Tumors](#)

SEC Filings

| Filing Date | Form |
|-------------|--------|
| 04/27/17 | 15-12G |
| 01/24/17 | EFFECT |
| 01/24/17 | EFFECT |
| 01/24/17 | EFFECT |

Upcoming Events

There are currently no events scheduled.

Corporate Governance

| | |
|--|--|
| William S. Barth | Chief Financial Officer |
| Todd H. Turnlund | VP of Research & Design |
| Jennifer Hoglin | Vice President of Global Marketing |
| Ben Beckham | Vice President of Global Sales |
| Brian A. Meltzer, M.D. | Chief Medical Officer and Vice President of Business Development |
| Rick Gaykowski | Vice President of Regulatory, Quality, and Clinical Affairs |

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Perseon 2015.